NeoGenomics, Inc.

Valuation Analysis

About the Company

NeoGenomics, Inc. en bref

NeoGenomics, Inc. (NEO) is currently trading at 9,71 € with a market capitalization of 1,3 Md €. The 52-week range spans from 4,12 € to 11,99 €; the current price is 19% below the yearly high. Year-over-year revenue growth stands at +11.1%.

💰 Dividende

NeoGenomics, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

9 analystes évaluent NeoGenomics, Inc. (NEO) au consensus : None. L'objectif de cours moyen est de 13,14 €, soit un potentiel de +35.27% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 9,60 € à 21,82 €.

NeoGenomics, Inc. : la thèse d'investissement en détail

NeoGenomics, Inc. (NEO) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 11.1% pace year-over-year, suggesting the business model continues to find new customers and pricing power.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 1.81, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves.

Valorisation en contexte

The EV/EBITDA multiple of 381.61x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The analyst consensus price target implies 35.27% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to above-average price swings, elevated short interest (7.67%).

Trading Data

Related Stocks in the Same Sector

Where can I buy NeoGenomics, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.